Tag Archives: NIH

The NIH’s View of Bayh-Dole Compliance, 8

We are working through the NIH’s policy manual on Bayh-Dole. We reach a helpful list. Some of the steps required by the regulation to retain intellectual property rights to subject inventions include: Report all subject inventions to NIH. Make efforts … Continue reading

Posted in Bayh-Dole | Tagged , , , | Leave a comment

The NIH’s View of Bayh-Dole Compliance, 7

We have come full circle through NIH’s garbled version of Bayh-Dole, having been referred by the NIH’s SBIR guidance back to the NIH’s policy manual regarblization of Bayh-Dole in section 8.2.4. Section 8.2 has a bunch of data and research … Continue reading

Posted in Bayh-Dole | Tagged , , | Leave a comment

The NIH’s View of Bayh-Dole Compliance, 6

Research Enterprise has been examining the NIH’s representation of Bayh-Dole. So far we have seen that the NIH persists in citing a 1995 document that gives “guidance” that the Supreme Court in Stanford v Roche (2011) rejected. But the NIH … Continue reading

Posted in Bayh-Dole | Tagged , , , , | Leave a comment

The NIH’s View of Bayh-Dole Compliance, 5

We are working NIH’s not so tasty guidance to participants in its SBIR and STTR programs directed at small businesses. We reach the NIH’s account of the “principal features” of Bayh-Dole, at least with regard to “intellectual property” requirements: Principal … Continue reading

Posted in Bayh-Dole | Tagged , , , , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 5

The NIH’s View of Bayh-Dole Compliance, 4

Here’s the NIH offering an overview of Bayh-Dole for its SBIR and STTR programs. Much of the “information” here appears to be drawn from an NIH Q&A document from 1995. That document, “A ’20-20′ View of Invention Reporting to the … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 4

The NIH’s View of Bayh-Dole Compliance, 3

We are working through NIH guidance on Bayh-Dole reporting requirements. In the process we are making note about how thoroughly NIH misrepresents Bayh-Dole. Sloppy? Indifferent? Does it matter? The next bit is going to be a bother: If it helps, … Continue reading

Posted in Bayh-Dole | Tagged , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 3

The NIH’s View of Bayh-Dole Compliance, 2

A while ago, I worked through a slide in an NIH presentation about Bayh-Dole compliance. The conclusion there was that the presentation was sloppy, lacked important details, and misrepresented the Bayh-Dole standard patent rights clause. There are other accounts of … Continue reading

Posted in Bayh-Dole | Tagged , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 2

Bayh-Dole the Monster

The Bayh-Dole Act makes a great deal about public interest. Throughout the law are gestures toward worthy objectives–use of inventions, manufacturing in the United States, government licenses, and the right of federal agencies to step if they need to. But … Continue reading

Posted in Bayh-Dole, Stanford v Roche | Tagged , , , , , | Comments Off on Bayh-Dole the Monster

The NIH’s View of Bayh-Dole Compliance

In 2015, Ann Hammersla gave a talk at an NIH Regional Seminar that include Bayh-Dole. There are numerous problems with Hammersla’s treatment of Bayh-Dole, but we’ll leave most of those for the attentive reader to pick through. Let’s look at … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on The NIH’s View of Bayh-Dole Compliance

The NIH’s complicity in faux Bayh-Dole and high drug prices

Here’s “A ’20-20′ View of Invention Reporting to the National Institutes of Health”–published by the NIH in 1995. 2. WHAT IS THE BAYH-DOLE ACT AND WHY IS IT IMPORTANT? The Bayh-Dole Act encourages researchers to patent and market their inventions … Continue reading

Posted in Bayh-Dole, History, Stanford v Roche | Tagged , , , , | Comments Off on The NIH’s complicity in faux Bayh-Dole and high drug prices